NIH seeks comments on broader biosafety rules for research
The National Institutes of Health is seeking public comment on a draft policy that would broaden biosafety oversight beyond research involving recombinant and synthetic nucleic-acid molecules.
NIH released the draft for comment on August 19, 2026, announced it on September 11, and the formal request for information was published in the Federal Register on September 14. Comments are due October 19, 2026.
The proposal is not final and does not immediately change requirements for laboratories or research institutions.
What NIH is proposing
NIH says the draft would replace the current NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules with a broader framework for research involving biohazards.
The proposed scope includes wild-type bacteria, viruses, fungi and parasites that can cause human disease. It also includes genetically modified cells, viruses and organisms; toxins; prions and other self-aggregating proteins; and cells or organisms containing those hazards.
The draft uses a risk-based structure. Different types of research would receive different levels of oversight, with higher-risk work subject to more extensive review and lower-risk work potentially eligible for more limited or delegated review. NIH says the approach is intended to reduce unnecessary burdens for lower-risk research while maintaining stronger oversight for work involving greater potential harm.
Which institutions and projects could be covered
Under the draft, the policy would apply to research supported in whole or in part by NIH, regardless of the funding level or mechanism. It would also apply to non-NIH-funded research conducted at an institution that receives any NIH funding.
The proposed reach would therefore extend beyond individual NIH grants. Universities, medical centers and other research organizations receiving NIH support could need to account for the policy when overseeing additional laboratory work conducted at their facilities.
The current NIH framework already applies to NIH-funded and certain non-NIH-funded research involving recombinant or synthetic nucleic-acid molecules at organizations that receive NIH support. The proposal would broaden the types of biological hazards covered by that institutional framework.
The draft states that, if NIH adopts a final policy, it would take effect six months after the final policy is published. Until then, the current framework remains in place, along with requirements administered by other federal agencies where applicable.
Expanded role for institutional biosafety committees
Institutional Biosafety Committees, or IBCs, would remain central to the proposed system. The committees would review and oversee covered research, assess risks, determine appropriate biosafety practices and monitor compliance.
Institutions would need NIH-approved Biosafety Assurances and would have broader responsibilities for biosafety governance, training, records and incident reporting. The draft also calls for public access, to the maximum extent possible, to information such as institutional biosafety procedures, IBC rosters, meeting minutes, incident reports and summaries of relevant training.
Those transparency provisions are part of the proposal. They are not new requirements that have already taken effect under this draft.
Why the change matters
For universities and laboratories, the central change would be the proposed move from a framework focused on recombinant and synthetic nucleic-acid research to one covering a wider set of biological hazards. Researchers working with naturally occurring disease-causing agents, toxins, prions or genetically modified organisms could fall within the proposed scope if their work is covered by the policy.
The draft would also place greater emphasis on institution-level risk assessment and give IBCs broader responsibilities. The practical effect on staffing, review timelines, documentation and compliance costs is not yet settled and could vary by institution and type of research.
The proposed policy would not replace requirements administered by other federal agencies, including the Centers for Disease Control and Prevention and the U.S. Department of Agriculture. Research could remain subject to multiple oversight systems.
What happens next
Researchers, universities, laboratory administrators and other members of the public may submit comments through October 19, 2026. NIH will review the responses before deciding whether to issue a final policy, revise the draft or take another step.
If NIH publishes a final policy, the draft states that it would become effective six months later. Until that process is complete, institutions should treat the document as a proposal rather than an immediate change in federal biosafety requirements.
Sources
Look for updates to this story
Discover more from Interactive News
Subscribe to get the latest posts sent to your email.